Zymeworks Competitors and Similar CompaniesClear all
Zymeworks's competitors and similar companies include NovoCure, Coherus BioSciences, Gossamer Bio and Foghorn Therapeutics.
 Zymeworks Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics. |  NovoCure NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors. |  Coherus BioSciences Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments. |  Gossamer Bio Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. |  Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. | |
Founding Date | Founding Date 2003 | Founding Date 2000 | Founding Date 2010 | Founding Date 2015 | Founding Date 2016 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Vancouver, CA HQ Seattle, US | Locations Redwood City, US HQ Camarillo, US | Locations San Diego, US HQ Dublin 2, IE | Locations Cambridge, US HQ Cambridge, US | |
Employees | Employees 45519% increase | Employees 1,453 | Employees 30615% decrease | Employees 11820% increase | Employees 16135% increase |
Valuation ($) | Valuation ($) 880.3 m | Valuation ($) 1.7 b | Valuation ($) 117.5 m | Valuation ($) 237.5 m | Valuation ($) 480.3 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $76m (FY, 2023) | Revenue (est.) $509.3m (FY, 2023) | Revenue (est.) $257.2m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $34.2m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods $128.3m (FY, 2023) | Cost of goods $159m (FY, 2023) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit $381.1m (FY, 2023) | Gross profit $98.3m (FY, 2023) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($118.7m) (FY, 2023) | Net income ($207m) (FY, 2023) | Net income ($237.9m) (FY, 2023) | Net income ($179.8m) (FY, 2023) | Net income ($98.4m) (FY, 2023) |
Operating ⚠ | |||||
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products 1 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 3 (FY, 2021) | Phase III Trials Products 1 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Trials Products Approved | Trials Products Approved N/A | Trials Products Approved 3 (FY, 2021) | Trials Products Approved 1 (FY, 2020) | Trials Products Approved N/A | Trials Products Approved N/A |
Funding | |||||
Total funding raised | Total funding raised $ 125.9m | Total funding raised N/A | Total funding raised $ 174.5m | Total funding raised $ 480m | Total funding raised $ 50m |
For sources of this data, please see the company profile
View Company Profiles
NovoCure
HQ
Saint Helier, JE
Employees
1,453
NovoCure is a company engaged in the development, manufacture, and commercialization of solutions for the treatment of solid tumors.
View companyCoherus BioSciences
HQ
Redwood City, US
Employees
306↓ 15% decrease
Coherus BioSciences is a biopharmaceutical company that focuses on the research, development, and commercialization of cancer treatments.
View companyGossamer Bio
HQ
San Diego, US
Employees
118↑ 20% increase
Gossamer Bio is a company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations.
View companyFoghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
View company